<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Risk of mycobacterial infection associated with biologic agents and JAK inhibitors</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Risk of mycobacterial infection associated with biologic agents and JAK inhibitors</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Risk of mycobacterial infection associated with biologic agents and JAK inhibitors</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kevin L Winthrop, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">C Fordham von Reyn, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 31, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Biologic agents and Janus kinase (JAK) inhibitors represent important treatment advances for a number of immune-mediated inflammatory conditions (including rheumatoid arthritis, the seronegative spondyloarthropathies, psoriasis, and inflammatory bowel disease) [<a href="#rid1">1,2</a>]. (See  <a class="medical medical_review" href="/d/html/7966.html" rel="external">"Overview of biologic agents in the rheumatic diseases"</a> and  <a class="medical medical_review" href="/d/html/130611.html" rel="external">"Overview of the Janus kinase inhibitors for rheumatologic and other inflammatory disorders"</a>.)</p><p>Use of these agents is associated with increased risk of tuberculosis (TB); all patients should be screened for TB infection prior to their use.</p><p>The approach to use of these agents in the context of risk for mycobacterial infections will be reviewed here. Other infectious complications of tumor necrosis factor-alpha inhibitors are discussed separately. (See  <a class="medical medical_review" href="/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects"</a> and  <a class="medical medical_review" href="/d/html/1410.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Bacterial, viral, and fungal infections"</a>.)</p><p class="headingAnchor" id="H3731715370"><span class="h1">GENERAL PRINCIPLES</span></p><p class="headingAnchor" id="H1147245367"><span class="h2">Biologic agents</span></p><p class="headingAnchor" id="H2"><span class="h3">TNF-alpha inhibitors</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Agents</strong> – Several tumor necrosis factor (TNF)-alpha inhibitors have been approved for the treatment of a variety of inflammatory illnesses (eg, rheumatoid arthritis, Crohn disease) by the US Food and Drug Administration:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">Infliximab</a> – A chimeric (mouse/human) anti-TNF-alpha monoclonal antibody</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">Adalimumab</a> – A fully human monoclonal anti-TNF-alpha antibody</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">Etanercept</a> – A soluble TNF-alpha receptor fusion protein</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8644" href="/d/drug information/8644.html" rel="external">Certolizumab pegol</a> – A pegylated Fab fragment of a humanized monoclonal antibody</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9086" href="/d/drug information/9086.html" rel="external">Golimumab</a> – A human monoclonal anti-TNF-alpha antibody</p><p></p><p class="bulletIndent1">Among the available biologics, these agents have the greatest impact on ability of the host to contain TB infection. They are discussed in further detail separately. (See  <a class="medical medical_review" href="/d/html/7966.html" rel="external">"Overview of biologic agents in the rheumatic diseases", section on 'TNF inhibition'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Effect on host defenses</strong> – Host defense against mycobacteria relies on the granulomatous response; this consists of sequestration of bacilli within granulomas, which are comprised of a central core of macrophages, multinucleated giant cells, and necrotic debris, surrounded by macrophages and lymphocytes [<a href="#rid3">3</a>]. </p><p></p><p class="bulletIndent1">TNF-alpha is required for orderly recruitment of these cells and for continued function of the granuloma [<a href="#rid4">4-6</a>]. The ability of macrophages to contain intracellular tuberculosis bacillary growth is also dependent on TNF-alpha [<a href="#rid7">7,8</a>]. (See  <a class="medical medical_review" href="/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects"</a>.)</p><p></p><p class="headingAnchor" id="H1629666057"><span class="h3">Other biologic agents</span><span class="headingEndMark"> — </span>Non-TNF biologic agents include <a class="drug drug_general" data-topicid="8526" href="/d/drug information/8526.html" rel="external">abatacept</a>, <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a>, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="132266" href="/d/drug information/132266.html" rel="external">anifrolumab</a>, <a class="drug drug_general" data-topicid="9514" href="/d/drug information/9514.html" rel="external">ustekinumab</a>, <a class="drug drug_general" data-topicid="113315" href="/d/drug information/113315.html" rel="external">sarilumab</a>, interleukin (IL)-17 blockers, and IL-23 blockers. (See  <a class="medical medical_review" href="/d/html/7966.html" rel="external">"Overview of biologic agents in the rheumatic diseases"</a>.)</p><p class="headingAnchor" id="H250872986"><span class="h3">JAK inhibitors</span><span class="headingEndMark"> — </span>JAK inhibitors include <a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">tofacitinib</a>, <a class="drug drug_general" data-topicid="118052" href="/d/drug information/118052.html" rel="external">baricitinib</a>, <a class="drug drug_general" data-topicid="122341" href="/d/drug information/122341.html" rel="external">upadacitinib</a>, <a class="drug drug_general" data-topicid="139596" href="/d/drug information/139596.html" rel="external">deucravacitinib</a>, and others. (See  <a class="medical medical_review" href="/d/html/130611.html" rel="external">"Overview of the Janus kinase inhibitors for rheumatologic and other inflammatory disorders"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Quantifying risk for TB</span><span class="headingEndMark"> — </span>The risk of tuberculosis (TB) and its timing varies depending on the agent. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk for TB varies depending on the immunosuppressive agent </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>TNF-alpha inhibitors</strong> – All TNF-alpha inhibitors are associated with increased risk of TB disease (active TB); the risk is greater for the anti-TNF monoclonal antibodies (<a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> and <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a>) than for the soluble receptor fusion protein <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> [<a href="#rid1">1</a>]. The risk associated with the newer monoclonal agents (certolizumab and <a class="drug drug_general" data-topicid="9086" href="/d/drug information/9086.html" rel="external">golimumab</a>) is presumed to be similar to the other anti-TNF monoclonal antibodies; however, for these agents the risk has not been established in population-based studies or compared with the other agents [<a href="#rid9">9,10</a>].</p><p></p><p class="bulletIndent2">The risk of TB among more than 13,000 patients receiving TNF-alpha inhibitors was evaluated in a national prospective observational study using data from the British Society for Rheumatology Biologics Register [<a href="#rid11">11</a>]. Among patients with rheumatoid arthritis receiving <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a>, or <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> (10,712 patients) or traditional disease-modifying antirheumatic drugs (DMARDs; 3232 patients), 40 episodes of TB occurred among those receiving TNF-alpha inhibitors; case rates for infliximab, adalimumab, and etanercept were 144, 136, and 39 cases per 100,000 person-years, respectively. No cases were reported in the DMARD cohort.</p><p></p><p class="bulletIndent2">In a Swedish study including more than 30,000 patients (of whom 4930 had rheumatoid arthritis, of whom 2500 received TNF-alpha inhibitors), the relative risk of TB among patients not treated with TNF-alpha inhibitors compared with the general population was 2.0 (95% CI 1.2-3.4); by contrast, the relative risk of TB among patients treated with TNF-alpha inhibitors compared with those not treated with TNF-alpha inhibitors was 4.0 (95% CI 1.3-12) [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent2">Potential explanations for differences in risk between TNF-alpha inhibitors include varying degrees of granuloma penetration, differential downregulation of TB antigen-stimulated interferon-gamma production, and varying effects upon antimicrobial-producing CD8 effector cells [<a href="#rid13">13-15</a>].</p><p></p><p class="bulletIndent2">Many of the TB cases associated with TNF-alpha inhibitors likely represent reactivation of TB infection (latent TB). The risk of TB correlates with background regional TB risk.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other non-TNF-alpha inhibitor biologics</strong> – Data on TB risk are limited for many of the non-TNF-alpha inhibitor biologics.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Abatacept</strong> – The risk with <a class="drug drug_general" data-topicid="8526" href="/d/drug information/8526.html" rel="external">abatacept</a> is lower than observed for TNF blockers; in a study including eight trials of abatacept and more than 4100 patients, the TB incidence was 0.07 per 100 patient-years [<a href="#rid16">16</a>]. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Tocilizumab</strong><strong>, </strong><strong>sarilumab</strong> (monoclonal antibodies blocking IL-6 signaling) – In a postmarketing surveillance study including more than 3800 patients with rheumatoid arthritis treated with <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a>, four patients developed TB (incidence 0.22 per 100 patient-years); all had been screened appropriately before starting therapy [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Rituximab</strong> (a chimeric monoclonal antibody targeted against the pan-B-cell marker CD20 to inhibit several B cell activities) – <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> is thought to carry lower risk than TNF blockers, although cases have been reported. In one study including more than 980 patients who received at least one dose of rituximab, with 3844 patient-years of follow-up, no cases of TB disease were observed [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/d/html/7501.html" rel="external">"Rituximab: Principles of use and adverse effects in rheumatoid arthritis"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Anifrolumab</strong><strong> </strong>(a fusion protein that<em> </em>binds to the costimulatory molecules CD80 and CD86 on antigen-presenting cells [APCs] to prevent T cell activation) – <a class="drug drug_general" data-topicid="132266" href="/d/drug information/132266.html" rel="external">Anifrolumab</a> inhibits type-1 interferon signaling. This could theoretically increase risk, but the actual risk is unknown. Within clinical trials, patients were screened for TB infection. Several patients converted to a positive interferon-gamma release assay (IGRA) during the trials, but no TB disease occurred.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Ustekinumab</strong><strong> </strong>– <a class="drug drug_general" data-topicid="9514" href="/d/drug information/9514.html" rel="external">Ustekinumab</a> blocks IL-12/23 and has not been observed to increase the risk of TB, although its label suggests screening for TB prior to its use.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>IL-17 blockers</strong> – IL-17 blockers carry no or very little risk of TB. No increased risk was observed in clinical trials, although rare cases have been reported in real world data. The labels for these therapeutics recommend screening for TB prior to starting them, based upon how pivotal clinical trials were conducted in which such screening was employed.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>IL-23 blockers</strong> – IL-23 blockers would not be expected to increase risk, and no increased risk has been observed with the use of these agents.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>JAK inhibitors</strong> – JAK inhibitors include <a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">tofacitinib</a>, <a class="drug drug_general" data-topicid="118052" href="/d/drug information/118052.html" rel="external">baricitinib</a>, <a class="drug drug_general" data-topicid="122341" href="/d/drug information/122341.html" rel="external">upadacitinib</a>, <a class="drug drug_general" data-topicid="139596" href="/d/drug information/139596.html" rel="external">deucravacitinib</a>, and others.</p><p></p><p class="bulletIndent2">In one study of <a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">tofacitinib</a> including data from phase 2, phase 3, and long-term extension clinical trial data from more than 5600 patients, in patients with rheumatoid arthritis treated with tofacitinib, 26 cases of TB disease were identified. The median time between start of tofacitinib and TB diagnosis was 64 weeks, and extrapulmonary disease was observed in 58 percent of cases [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent2">Cases were also reported above background population rates in the <a class="drug drug_general" data-topicid="118052" href="/d/drug information/118052.html" rel="external">baricitinib</a> program in rheumatoid arthritis, and cases have also been observed with <a class="drug drug_general" data-topicid="122341" href="/d/drug information/122341.html" rel="external">upadacitinib</a> in randomized controlled trials for rheumatoid arthritis and other conditions [<a href="#rid20">20,21</a>].</p><p></p><p class="bulletIndent2">The development program for <a class="drug drug_general" data-topicid="139596" href="/d/drug information/139596.html" rel="external">deucravacitinib</a> did not report any TB cases, although patients were screened prior to trial entry [<a href="#rid22">22,23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Variable timing of TB disease onset</strong> – Treatment with <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> is associated with a shorter time to development of TB disease compared with <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> and <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a British study including more than 13,000 patients receiving TNF-alpha inhibitors, the median time to development of TB disease was shortest for <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> (5.5 months) compared with <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> (13.4 months) and <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a> (18.5 months)  (<a class="graphic graphic_figure graphicRef70906" href="/d/graphic/70906.html" rel="external">figure 1</a>) [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Similarly, in a study including 233,000 patients treated with <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> and 113,000 patients treated with <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a>, 43 percent of infliximab-associated cases of TB disease occurred during the first 90 days of treatment, a pattern consistent with reactivation of TB infection; by contrast, etanercept-associated TB cases were distributed evenly throughout during the reporting period, with only 10 percent occurring during the first 90 days of treatment [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1">The basis for variable times of onset is uncertain; the observations may reflect differential drug effects on reactivation risk, occurrence of new infection, or the waning effects of prior <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a> therapy for prevention of reactivation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Influence of underlying rheumatoid arthritis</strong> – Rheumatoid arthritis has been associated with increased risk for the development of TB in some studies [<a href="#rid12">12,25,26</a>], but not others [<a href="#rid27">27</a>]. TNF-alpha inhibitors appear to increase the risk of TB beyond that which may be associated with rheumatoid arthritis itself.</p><p></p><p class="headingAnchor" id="H584418633"><span class="h1">TUBERCULOSIS</span></p><p class="headingAnchor" id="H2689389423"><span class="h2">TB infection</span></p><p class="headingAnchor" id="H15"><span class="h3">Screening</span><span class="headingEndMark"> — </span>All patients who are planning to undergo treatment with a biologic agent or JAK inhibitor should be screened for tuberculosis (TB) infection prior to initiation of immunosuppressive therapy [<a href="#rid2">2,28</a>].</p><p></p><p class="headingAnchor" id="H2097433905"><span class="h4">Prior to immunosuppression</span><span class="headingEndMark"> — </span>In patients who screen positive and are treated for TB infection prior to initiation of a biologic agent or JAK inhibitor, the risk for subsequent development of TB disease is low, although not eliminated [<a href="#rid9">9,19,29</a>]. As an example, in a registry study including more than 7800 patients with rheumatic conditions in Spain treated with tumor necrosis factor (TNF)-alpha inhibitors , implementation of recommendations for TB screening were associated with a decline in TB disease rates by 78 percent (incidence risk ratio [IRR] 0.22, 95% CI 0.03-0.88) [<a href="#rid30">30</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Components of screening</strong> – Screening should include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Clinical history, including: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Epidemiologic risk factors for TB exposure (See  <a class="medical medical_review" href="/d/html/8018.html" rel="external">"Epidemiology of tuberculosis", section on 'Risk factors'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Clinical manifestations of TB disease (cough &gt;2 weeks, fevers, night sweats, weight loss)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Physical examination</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Interferon-gamma release assay (IGRA), or if not available, a <a class="drug drug_general" data-topicid="10029" href="/d/drug information/10029.html" rel="external">tuberculin skin test</a> (TST) [<a href="#rid31">31,32</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to screening</strong> – Our approach to screening for TB infection varies depending upon whether the patient has risk factors for TB infection:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Presence of risk factors for TB infection</strong> – Using a single screening test does not identify all patients at risk for TB infection; false-negative results are more likely in immunocompromised individuals [<a href="#rid9">9,33-35</a>]. Accordingly, in immunosuppressed patients with risk factors for prior TB exposure, we favor a dual testing strategy, which consists of checking a second test if the first test is negative  (<a class="graphic graphic_algorithm graphicRef112540" href="/d/graphic/112540.html" rel="external">algorithm 1</a>) [<a href="#rid28">28</a>]. </p><p></p><p class="bulletIndent2">For the initial screening test, we prefer an IGRA over TST; IGRA is likely more sensitive in the setting of immunosuppression, it can be accomplished in one visit, and it eliminates uncertainty regarding history of Bacille Calmette-Guérin (BCG) vaccination. </p><p></p><p class="bulletIndent2">For previously exposed and anergic individuals, beginning with TST (followed by IGRA) may improve sensitivity.</p><p></p><p class="bulletIndent2">For repeat testing, either the same IGRA or another assay may be used. Available IGRAs include the QuantiFERON-TB Gold and the T-SPOT.TB assay.</p><p></p><p class="bulletIndent2">Issues related to IGRAs are discussed further separately. (See  <a class="medical medical_review" href="/d/html/15352.html" rel="external">"Use of interferon-gamma release assays for diagnosis of tuberculosis infection (tuberculosis screening) in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Absence of risk factors for TB infection</strong> – For patients without risk factors for TB infection, we screen with a single test (preferably IGRA)  (<a class="graphic graphic_algorithm graphicRef112541" href="/d/graphic/112541.html" rel="external">algorithm 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with positive screening test</strong> – For patients with positive IGRA or TST and no clinical manifestations of TB, a chest radiograph should be obtained  (<a class="graphic graphic_algorithm graphicRef142006" href="/d/graphic/142006.html" rel="external">algorithm 3</a>) [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Normal chest radiograph</strong> – For patients with normal chest radiograph, treatment for TB infection should be administered.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Abnormal chest radiograph</strong> – For patients with abnormal chest radiograph, three sputum specimens should be obtained for acid-fast bacilli smear, mycobacterial culture, and nucleic acid amplification testing [<a href="#rid28">28</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with negative sputum microbiologic evaluation, treatment for TB infection should be administered. The immunosuppressive agent may be administered after the patient has completed at least one month of treatment. (See  <a class="medical medical_review" href="/d/html/8017.html" rel="external">"Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults without HIV infection"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with positive sputum microbiologic evaluation, treatment for TB disease should be administered. The immunosuppressive agent may be administered after the patient has completed antituberculous therapy. (See  <a class="medical medical_review" href="/d/html/8015.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"</a>.)</p><p></p><p class="bulletIndent1">For patients with clinical manifestations of TB, the diagnostic approach is outlined separately. (See  <a class="medical medical_review" href="/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults"</a>.)</p><p></p><p class="headingAnchor" id="H1024445132"><span class="h4">Surveillance screening</span><span class="headingEndMark"> — </span>For patients on a biologic agent or JAK inhibitor who have ongoing risk of TB exposure, repeat screening for TB infection should be performed annually [<a href="#rid2">2,36</a>]. TST may be preferred for repeat screening since IGRA test conversions and reversions may be difficult to interpret [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/d/html/115049.html" rel="external">"Tuberculosis infection (latent tuberculosis) in adults: Approach to diagnosis (screening)", section on 'Diagnostic approach'</a>.)</p><p>For patients on a biologic agent or JAK inhibitor with no ongoing risk of TB exposure in the setting of negative initial screening or successful completion of treatment for TB infection, repeat screening is not necessary. </p><p class="headingAnchor" id="H16"><span class="h3">Management</span></p><p class="headingAnchor" id="H1719387844"><span class="h4">Indications for treatment</span><span class="headingEndMark"> — </span>For patients planning to undergo treatment with a biologic agent or JAK inhibitor, indications for treatment of TB infection include:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with positive IGRA or positive TST (≥5 mm induration) and no evidence of TB disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with prior diagnosis of TB infection who did not complete treatment, even in the setting of negative IGRA or TST (&lt;5 mm)</p><p></p><p>For patients with negative or indeterminate screening test results for TB infection, treatment decisions should be individualized based on the risk of TB exposure and the likelihood that a negative test may represent a false-negative result. Treatment may be warranted for patients with a strong likelihood of prior TB exposure (eg, evidence of remote TB disease on chest radiography [regional fibrosis with or without hilar lymphadenopathy], history of close contact with a TB case, or residence in a country with high TB incidence  (<a class="graphic graphic_table graphicRef111123" href="/d/graphic/111123.html" rel="external">table 1</a>)). We have a lower threshold for treating patients who were immunosuppressed at the time of testing for TB infection since immunosuppression reduces the sensitivity of the screening tests.</p><p class="headingAnchor" id="H3267331429"><span class="h4">Clinical approach</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antimycobacterial therapy</strong> – Patients who warrant treatment for TB infection may be treated with any approved regimen  (<a class="graphic graphic_table graphicRef117939" href="/d/graphic/117939.html" rel="external">table 2</a>); while rifampin-based regimens are preferred, drug-drug interactions should be considered carefully. As an example, for patients on <a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">tofacitinib</a> who warrant treatment for TB infection, <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a> monotherapy is preferred given the drug interaction between tofacitinib and <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> (concurrent use can decrease tofacitinib bioavailability by 80 percent) [<a href="#rid1">1</a>]. </p><p></p><p class="bulletIndent1">Issues related to treatment of TB infection are discussed further separately. (See  <a class="medical medical_review" href="/d/html/8017.html" rel="external">"Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults without HIV infection", section on 'Clinical approach'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration of the immunosuppressive agent</strong> – Patients can start the biologic or JAK inhibitor at any time after starting preventive therapy for TB infection. We prefer to administer the immunosuppressive agent once the patient has completed at least several weeks of antituberculous treatment [<a href="#rid9">9,38</a>]; this approach is in agreement with the American College of Rheumatology and gives the clinician time to verify the patient is tolerating antituberculous treatment [<a href="#rid2">2</a>].</p><p></p><p class="headingAnchor" id="H2012328535"><span class="h2">TB disease</span></p><p class="headingAnchor" id="H1020816722"><span class="h3">Clinical manifestations</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – General issues related to clinical manifestations of TB disease are discussed separately. (See  <a class="medical medical_review" href="/d/html/7026.html" rel="external">"Pulmonary tuberculosis: Clinical manifestations and complications"</a> and  <a class="medical medical_review" href="/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atypical manifestations</strong> – For patients who develop TB disease in association with use of a biologic agent or JAK inhibitor, the likelihood of extrapulmonary involvement, smear-negative disease, and disseminated disease is higher compared with patients who develop TB disease in the absence of these agents [<a href="#rid14">14,39-42</a>]. In one report including 70 patients with TB associated with <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, 57 percent had extrapulmonary disease [<a href="#rid43">43</a>]. Patients with disseminated TB may lack pulmonary symptoms and have normal chest radiographs, leading to diagnostic delay. (See  <a class="medical medical_review" href="/d/html/8024.html" rel="external">"Clinical manifestations, diagnosis, and treatment of miliary tuberculosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Paradoxical worsening</strong> – A paradoxical worsening of TB symptoms can occur after starting TB treatment in patients who discontinue immunosuppressive therapy; this is known as immune reconstitution inflammatory syndrome (IRIS) [<a href="#rid44">44-46</a>]. In one study IRIS developed in 7 percent of patients developed TB disease after TNF-alpha inhibitor withdrawal; IRIS occurred a median of 45 days after starting TB treatment and 110 days after the last TNF-alpha inhibitor dose [<a href="#rid47">47,48</a>]. (See  <a class="medical medical_review" href="/d/html/3762.html" rel="external">"Immune reconstitution inflammatory syndrome", section on 'Tuberculosis'</a>.)</p><p></p><p class="headingAnchor" id="H1007488682"><span class="h3">Management</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antimycobacterial therapy</strong> – Treatment of TB disease is discussed separately. (See  <a class="medical medical_review" href="/d/html/8015.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"</a> and  <a class="medical medical_review" href="/d/html/8024.html" rel="external">"Clinical manifestations, diagnosis, and treatment of miliary tuberculosis", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to immunosuppression </strong>– Patients on a biologic agent or JAK inhibitor at the time of TB diagnosis should discontinue it; it may be resumed following completion of treatment for TB disease. Decisions regarding resumption of immunosuppression prior to completion of TB treatment should be guided by clinical circumstances; this may be feasible for certain patients in the setting of drug-susceptible TB, sputum culture conversion to negative, and clinical improvement. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immune reconstitution inflammatory syndrome</strong> – Issues related to management of IRIS are discussed separately. (See  <a class="medical medical_review" href="/d/html/8030.html" rel="external">"Treatment of pulmonary tuberculosis in adults with HIV infection: Follow-up after initiation of therapy", section on 'Immune reconstitution inflammatory syndrome'</a>.)</p><p></p><p class="headingAnchor" id="H533416427"><span class="h1">NONTUBERCULOUS MYCOBACTERIAL DISEASE</span></p><p class="headingAnchor" id="H82732327"><span class="h2">Epidemiology</span><span class="headingEndMark"> — </span>In areas of low tuberculosis (TB) incidence, nontuberculous mycobacterial (NTM) disease occurs more commonly than TB among patients on biologic agents or JAK inhibitors. NTM disease in the setting of these agents is most often attributed to use of tumor necrosis factor (TNF)-alpha inhibitors. In one study including more than 8400 patients with rheumatoid arthritis on TNF-alpha inhibitors, the incidence of NTM disease was 106 per 100,000; this was approximately double the rate among patients with rheumatoid arthritis and no TNF-alpha inhibitor exposure  (<a class="graphic graphic_figure graphicRef107763" href="/d/graphic/107763.html" rel="external">figure 2</a>) [<a href="#rid49">49</a>]. In addition, rheumatoid arthritis is an independent risk factor for NTM disease (irrespective of risk associated with use of immunosuppressive agents) [<a href="#rid50">50,51</a>].</p><p>In a review including 105 patients receiving TNF-alpha inhibitors with NTM disease, the median age was 62 years, females predominated (65 percent), and most had rheumatoid arthritis (70 percent) [<a href="#rid52">52</a>]. Most patients were also taking <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> (65 percent) or <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (55 percent). <em>M. avium </em>was the most common NTM species, occurring in 50 percent of patients. Extrapulmonary disease was observed in 44 percent of cases, including involvement of skin and soft tissues (26 percent), bones or joints (9 percent), disseminated disease (8 percent), or the eye (1 percent).</p><p class="headingAnchor" id="H533416546"><span class="h2">Clinical manifestations and diagnosis</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – NTM infection of the lungs often occurs in the context of preexisting lung disease, especially bronchiectasis, chronic obstructive pulmonary disease (COPD), pneumoconiosis, cystic fibrosis, or previous tuberculosis. Clinical manifestations include cough, fatigue, malaise, fever, weight loss, dyspnea, hemoptysis, and chest discomfort. (See  <a class="medical medical_review" href="/d/html/5342.html" rel="external">"Overview of nontuberculous mycobacterial infections"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – There is no established screening test for NTM infection. Diagnostic evaluation includes chest computed tomography (CT) and culture of respiratory specimens; this is discussed further separately. (See  <a class="medical medical_review" href="/d/html/5346.html" rel="external">"Diagnosis of nontuberculous mycobacterial infections of the lungs"</a>.)</p><p></p><p class="headingAnchor" id="H533416592"><span class="h2">Management</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antimycobacterial therapy</strong> – Issues related to treatment of NTM infections are discussed separately. (See  <a class="medical medical_review" href="/d/html/5342.html" rel="external">"Overview of nontuberculous mycobacterial infections"</a> and  <a class="medical medical_review" href="/d/html/5341.html" rel="external">"Treatment of <i>Mycobacterium avium </i>complex pulmonary infection in adults"</a> and  <a class="medical medical_review" href="/d/html/13995.html" rel="external">"Treatment of osteomyelitis due to nontuberculous mycobacteria in adults"</a> and  <a class="medical medical_review" href="/d/html/5347.html" rel="external">"Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration of the immunosuppressive agent</strong> – Biologic agents and JAK inhibitors should be discontinued in patients with NTM disease. The optimal approach to timing for resumption is uncertain given lack of data; the approach should be individualized based on clinical factors including the pathogen, disease burden, and severity of the underlying inflammatory condition.</p><p></p><p class="headingAnchor" id="H21"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of tuberculosis (TB)</strong> – Use of biologic agents and Janus kinase (JAK) inhibitors is associated with increased risk of TB disease. The risk of TB and its timing are variable depending on the agent. (See <a class="local">'Quantifying risk for TB'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TB infection</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Screening prior to immunosuppression</strong> – All patients who are planning to undergo treatment with a biologic agent or JAK inhibitor should be screened for TB infection prior to initiation of immunosuppressive therapy. (See <a class="local">'Screening'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Screening should include clinical history, physical examination, and a screening test (preferably interferon-gamma release assay [IGRA])  (<a class="graphic graphic_algorithm graphicRef112540" href="/d/graphic/112540.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef112541" href="/d/graphic/112541.html" rel="external">algorithm 2</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with positive IGRA or <a class="drug drug_general" data-topicid="10029" href="/d/drug information/10029.html" rel="external">tuberculin skin test</a> (TST) and no clinical manifestations of TB, a chest radiograph should be obtained  (<a class="graphic graphic_algorithm graphicRef142006" href="/d/graphic/142006.html" rel="external">algorithm 3</a>). For patients with abnormal chest radiograph, three sputum specimens should be obtained. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Surveillance screening</strong> – For patients on a biologic agent or JAK inhibitor who have ongoing risk of TB exposure, repeat screening for TB infection should be performed annually. (See <a class="local">'Surveillance screening'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Patients with TB infection</strong> – For patients who are planning to undergo treatment with a biologic agent or JAK inhibitor, we recommend treatment for those who are diagnosed with TB infection or have a history of inadequately treated TB infection (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Indications for treatment'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Patients with negative or indeterminate results</strong> – For patients with negative or indeterminate screening test results for TB infection, treatment decisions should be individualized based on the risk of TB exposure and the likelihood that a negative test may represent a false-negative result. (See <a class="local">'Indications for treatment'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Regimen selection</strong> – Patients who warrant treatment for TB infection may be treated with any approved regimen  (<a class="graphic graphic_table graphicRef117939" href="/d/graphic/117939.html" rel="external">table 2</a>); while rifampin-based regimens are preferred, drug-drug interactions should be considered carefully. (See <a class="local">'Clinical approach'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Initiating immunosuppression</strong> – Patients can start the biologic or JAK inhibitor at any time after starting preventive therapy for TB infection. We prefer to administer the immunosuppressive agent once the patient has completed at least several weeks of antituberculous treatment. (See <a class="local">'Clinical approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TB disease</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical manifestations</strong> – The likelihood of extrapulmonary TB, smear-negative disease, and disseminated disease may be higher among patients on biologic agents or JAK inhibitors. In addition, a paradoxical worsening of TB symptoms can occur after starting TB treatment in patients who discontinue immunosuppressive therapy. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management</strong> – Patients on a biologic agent or JAK inhibitor at the time of TB diagnosis should discontinue it; it may be resumed following completion of treatment for TB disease. Decisions regarding resumption of immunosuppression prior to completion of TB treatment should be guided by clinical circumstances. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nontuberculous mycobacterial (NTM) disease</strong> – In areas of low TB incidence, NTM disease occurs more commonly than TB among patients on biologic agents or JAK inhibitors. Immunosuppressive agents should be discontinued in patients with NTM disease. The optimal approach to timing for resumption is uncertain; it should be individualized based on clinical factors. (See <a class="local">'Nontuberculous mycobacterial disease'</a> above.)</p><p></p><p class="headingAnchor" id="H533416819"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Robert S Wallis, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Calabrese C, Winthrop KL. Mycobacterial Infections Potentiated by Biologics. Infect Dis Clin North Am 2020; 34:413.</a></li><li><a class="nounderline abstract_t">Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 2016; 68:1.</a></li><li><a class="nounderline abstract_t">Randhawa PS. Lymphocyte subsets in granulomas of human tuberculosis: an in situ immunofluorescence study using monoclonal antibodies. Pathology 1990; 22:153.</a></li><li><a class="nounderline abstract_t">Algood HM, Lin PL, Flynn JL. Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis 2005; 41 Suppl 3:S189.</a></li><li><a class="nounderline abstract_t">Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3:148.</a></li><li><a class="nounderline abstract_t">Lin PL, Myers A, Smith L, et al. Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model. Arthritis Rheum 2010; 62:340.</a></li><li><a class="nounderline abstract_t">Bekker LG, Freeman S, Murray PJ, et al. TNF-alpha controls intracellular mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-independent pathways. J Immunol 2001; 166:6728.</a></li><li><a class="nounderline abstract_t">Clay H, Volkman HE, Ramakrishnan L. Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death. Immunity 2008; 29:283.</a></li><li><a class="nounderline abstract_t">Hsia EC, Schluger N, Cush JJ, et al. Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Arthritis Rheum 2012; 64:2068.</a></li><li><a class="nounderline abstract_t">Bykerk VP, Cush J, Winthrop K, et al. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials. Ann Rheum Dis 2015; 74:96.</a></li><li><a class="nounderline abstract_t">Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69:522.</a></li><li><a class="nounderline abstract_t">Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005; 52:1986.</a></li><li><a class="nounderline abstract_t">Bruns H, Meinken C, Schauenberg P, et al. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest 2009; 119:1167.</a></li><li><a class="nounderline abstract_t">Saliu OY, Sofer C, Stein DS, et al. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 2006; 194:486.</a></li><li><a class="nounderline abstract_t">Plessner HL, Lin PL, Kohno T, et al. Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis 2007; 195:1643.</a></li><li><a class="nounderline abstract_t">Weinblatt ME, Moreland LW, Westhovens R, et al. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. J Rheumatol 2013; 40:787.</a></li><li><a class="nounderline abstract_t">Harigai M, Ishiguro N, Inokuma S, et al. Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2016; 26:491.</a></li><li><a class="nounderline abstract_t">Winthrop KL, Saag K, Cascino MD, et al. Long-Term Safety of Rituximab in Rheumatoid Arthritis: Analysis From the SUNSTONE Registry. Arthritis Care Res (Hoboken) 2018; 71:993.</a></li><li><a class="nounderline abstract_t">Winthrop KL, Park SH, Gul A, et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis 2016; 75:1133.</a></li><li><a class="nounderline abstract_t">Nash P, Kerschbaumer A, Dörner T, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis 2021; 80:71.</a></li><li><a class="nounderline abstract_t">Winthrop KL, Harigai M, Genovese MC, et al. Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Ann Rheum Dis 2020; 79:1290.</a></li><li><a class="nounderline abstract_t">Strober B, Thaçi D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol 2023; 88:40.</a></li><li><a class="nounderline abstract_t">Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol 2023; 88:29.</a></li><li><a class="nounderline abstract_t">Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38:1261.</a></li><li><a class="nounderline abstract_t">Carmona L, Hernández-García C, Vadillo C, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003; 30:1436.</a></li><li><a class="nounderline abstract_t">Arkema EV, Jonsson J, Baecklund E, et al. Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments? Ann Rheum Dis 2015; 74:1212.</a></li><li><a class="nounderline abstract_t">Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50:372.</a></li><li><a class="nounderline abstract_t">Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis 2017; 64:e1.</a></li><li><a class="nounderline abstract_t">Mariette X, Vencovsky J, Lortholary O, et al. The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region. RMD Open 2015; 1:e000044.</a></li><li><a class="nounderline abstract_t">Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52:1766.</a></li><li><a class="nounderline abstract_t">Mazurek GH, Jereb J, Vernon A, et al. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 2010; 59:1.</a></li><li><a class="nounderline abstract_t">Canadian Tuberculosis Committee. Recommendations on Interferon Gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection - 2010 Update. Can Commun Dis Rep 2010; 36:1.</a></li><li><a class="nounderline abstract_t">Kleinert S, Tony HP, Krueger K, et al. Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-γ release assays under real-life conditions. Ann Rheum Dis 2012; 71:1791.</a></li><li><a class="nounderline abstract_t">Mariette X, Baron G, Tubach F, et al. Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy. Ann Rheum Dis 2012; 71:1783.</a></li><li><a class="nounderline abstract_t">Winthrop KL, Weinblatt ME, Daley CL. You can't always get what you want, but if you try sometimes (with two tests--TST and IGRA--for tuberculosis) you get what you need. Ann Rheum Dis 2012; 71:1757.</a></li><li><a class="nounderline abstract_t">Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64:625.</a></li><li><a class="nounderline abstract_t">Amour MA, Rees CA, Munseri PJ, et al. Serial T-SPOT.TB responses in Tanzanian adolescents: Transient, persistent and irregular conversions. PLoS One 2022; 17:e0268685.</a></li><li class="breakAll">Centers for Disease Control and Prevention, National Institutes of Health, and Infectious Diseases Society of America guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf (Accessed on November 23, 2016).</li><li><a class="nounderline abstract_t">Mohan AK, Coté TR, Block JA, et al. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004; 39:295.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Tuberculosis associated with blocking agents against tumor necrosis factor-alpha--California, 2002-2003. MMWR Morb Mortal Wkly Rep 2004; 53:683.</a></li><li><a class="nounderline abstract_t">Hill PC, Brookes RH, Fox A, et al. Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia. Clin Infect Dis 2004; 38:966.</a></li><li><a class="nounderline abstract_t">Katrak SS, Li R, Reynolds S, et al. Association of Tumor Necrosis Factor α Inhibitor Use with Diagnostic Features and Mortality of Tuberculosis in the United States, 2010-2017. Open Forum Infect Dis 2022; 9:ofab641.</a></li><li><a class="nounderline abstract_t">Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098.</a></li><li><a class="nounderline abstract_t">Arend SM, Leyten EM, Franken WP, et al. A patient with de novo tuberculosis during anti-tumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin Infect Dis 2007; 45:1470.</a></li><li><a class="nounderline abstract_t">Garcia Vidal C, Rodríguez Fernández S, Martínez Lacasa J, et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 2005; 40:756.</a></li><li><a class="nounderline abstract_t">Wallis RS, van Vuuren C, Potgieter S. Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis 2009; 48:1429.</a></li><li><a class="nounderline abstract_t">Rivoisy C, Tubach F, Roy C, et al. Paradoxical anti-TNF-associated TB worsening: Frequency and factors associated with IRIS. Joint Bone Spine 2016; 83:173.</a></li><li><a class="nounderline abstract_t">Hachisu Y, Koga Y, Kasama S, et al. Treatment with Tumor Necrosis Factor-α Inhibitors, History of Allergy, and Hypercalcemia Are Risk Factors of Immune Reconstitution Inflammatory Syndrome in HIV-Negative Pulmonary Tuberculosis Patients. J Clin Med 2019; 9.</a></li><li><a class="nounderline abstract_t">Winthrop KL, Baxter R, Liu L, et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 2013; 72:37.</a></li><li><a class="nounderline abstract_t">Yeh JJ, Wang YC, Sung FC, Kao CH. Rheumatoid arthritis increases the risk of nontuberculosis mycobacterial disease and active pulmonary tuberculosis. PLoS One 2014; 9:e110922.</a></li><li><a class="nounderline abstract_t">Winthrop KL, Iseman M. Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy. Nat Rev Rheumatol 2013; 9:524.</a></li><li><a class="nounderline abstract_t">Winthrop KL, Chang E, Yamashita S, et al. Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. Emerg Infect Dis 2009; 15:1556.</a></li></ol></div><div id="topicVersionRevision">Topic 1411 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32444014" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Mycobacterial Infections Potentiated by Biologics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26545940" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2243727" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Lymphocyte subsets in granulomas of human tuberculosis: an in situ immunofluorescence study using monoclonal antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15983898" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12614731" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20112395" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11359829" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : TNF-alpha controls intracellular mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-independent pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18691913" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22238071" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Interferon-γrelease assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24092417" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19854715" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15986370" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19381021" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16845632" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17471434" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23588946" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26635183" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30295434" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Long-Term Safety of Rituximab in Rheumatoid Arthritis: Analysis From the SUNSTONE Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26318385" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33158881" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32788396" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Infections in baricitinib clinical trials for patients with active rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36115523" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35820547" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15127338" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Granulomatous infectious diseases associated with tumor necrosis factor antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12858438" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Increased risk of tuberculosis in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24608401" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14872478" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27932390" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26509064" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15934089" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20577159" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Recommendations on Interferon Gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection - 2010 Update</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22586160" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-γrelease assays under real-life conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22258485" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Influence of replacing tuberculin skin test with ex vivo interferonγrelease assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22975752" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : You can't always get what you want, but if you try sometimes (with two tests--TST and IGRA--for tuberculosis) you get what you need.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22473917" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35749397" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Serial T-SPOT.TB responses in Tanzanian adolescents: Transient, persistent and irregular conversions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35749397" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Serial T-SPOT.TB responses in Tanzanian adolescents: Transient, persistent and irregular conversions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15306993" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15295313" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Tuberculosis associated with blocking agents against tumor necrosis factor-alpha--California, 2002-2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15034828" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35106318" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Association of Tumor Necrosis FactorαInhibitor Use with Diagnostic Features and Mortality of Tuberculosis in the United States, 2010-2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11596589" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17990230" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A patient with de novo tuberculosis during anti-tumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15714425" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19364287" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Adalimumab treatment of life-threatening tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26677996" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Paradoxical anti-TNF-associated TB worsening: Frequency and factors associated with IRIS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31905985" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Treatment with Tumor Necrosis Factor-αInhibitors, History of Allergy, and Hypercalcemia Are Risk Factors of Immune Reconstitution Inflammatory Syndrome in HIV-Negative Pulmonary Tuberculosis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22523429" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Mycobacterial diseases and antitumour necrosis factor therapy in USA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25337995" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Rheumatoid arthritis increases the risk of nontuberculosis mycobacterial disease and active pulmonary tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23797309" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19861045" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
